Lundbeckfonden Emerge
7
51M
4
0.64
1
0.43
- Areas of investment
Summary
In 2012 was created Lundbeckfonden Emerge, which is appeared as Corporate Investor. The venture was found in Europe in Denmark. The main department of described Corporate Investor is located in the Copenhagen.
The common things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2019. The fund is constantly included in less than 2 deals per year.
Among the most popular portfolio startups of the fund, we may highlight NMD Pharma, AFYX Therapeutics. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Medical. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Denmark.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the Lundbeckfonden Emerge, startups are often financed by Novo Seeds, Sofinnova Investments, EASME - EU Executive Agency for SMEs. The meaningful sponsors for the fund in investment in the same round are Novo Seeds, Sofinnova Partners, Sofinnova Investments. In the next rounds fund is usually obtained by Novo Seeds, Sofinnova Partners, INKEF Capital.
Investments analytics
Analytics
- Total investments
- 7
- Lead investments
- 1
- Rounds per year
- 0.64
- Follow on index
- 0.43
- Investments by industry
- Biotechnology (7)
- Pharmaceutical (5)
- Medical (3)
- Health Care (3)
- Therapeutics (3) Show 3 more
- Investments by region
-
- Denmark (7)
- Peak activity year
- 2021
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| NMD Pharma | 15 Nov 2023 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 88M | Central Denmark Region, Aarhus, Denmark |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.